Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Starts Presentation at 29th Annual ROTH Conference
Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which has completed Phase I single and multiple dose trials, an orally administered and small-molecule liver-directed selective thyroid hormone receptor-beta agonist for use in the treatment of nonalcoholic steatohepatitis (NASH), and heterozygous and homozygous familial hypercholesterolemia (FH) to lower LDL cholesterol, triglyceride levels, and Lp(a). For more information, visit the company’s website at www.madrigalpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…







